-
Most Recent
Search Results
240 results for dgse
5 Exotic ETFs to Buy for a Better Portfolio in 2019
A dose of out of box ETFs could do your portfolio good next year. Here are five great choices to build a better portfolio.
Novavax Stock Leads the Board on Wall Street but Lags on Main Street
NVAX stock is up over 3,000% this year yet it’s not the one with the doses on the streets. Best to trade the stock while…
GlaxoSmithKline and Sanofi Stock Rally on EU Vaccine Deal
GlaxoSmithKline and Sanofi stock are rallying in early trading on Friday thanks to news they would supply the EU 300 million vaccine doses.
Ocugen Looks Very Dicey at Current Levels
Ocugen believes it can distribute 100 million doses of a Covid-19 vaccine in the U.S. But this looks like a long shot for OCGN stock.
Looking for Great Bank Stocks to Buy? Look North.
Canadian bank stocks offer plenty of upside … and a good dose of safety to boot. Check out these 3 Canadian bank stocks to buy…
Memo to Bill Gross: The U.S. Is Not Greece
Once again, Pimco’s boss offers a big dose of unhelpful opinion, and his lumping the U.S. in with Greece and Spain is just plain wrong.
Biogen (BIIB): Why Aducanumab Excitement Might Be Overblown
Biogen Inc (BIIB) recently shot up after reporting positive results from aducanumab’s phase 1b study. However, there are some important takeaways from the report that…
Novavax Stock Is Alluringly Attractive at This Stage
Novavax is close to securing FDA approval for its Covid-19 vaccine yet NVAX stock is down since the end of January. What gives?
After Patent News, Aurinia Pharmaceuticals Still Has More to Prove
Is Aurinia’s patent news a big deal or a modest advance? Here’s why investors have mixed feelings about AUPH stock.
Why Geron Corporation (GERN), Polaris Industries Inc. (PII) and VimpelCom Ltd (ADR) (VIP) Are 3 of Today’s Worst Stocks
Polaris (PII), VimpelCom (VIP) and Geron (GERN) were conspicuously left out of Monday’s rebound rally. Here’s what you need to know.
Why Is Novavax (NVAX) Up 30% Today?
While Novavax secured an agreement with the Canadian government over unused Covid-19 vaccines, NVAX stock remains risky.
Novavax Looks Like a Winner With Its Vaccine Results
Novavax looks like a winner with its positive Covid-19 vaccine results. NVAX stock is worth at least 35% more than today based on widespread acceptance…
Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?
Stoke Therapeutics stock is up on Tuesday as STOK shares see heavy trading alongside recent positive clinical trial data.
Avoid Novavax for Now, Until the Picture Clears Up
NVAX stock may have seen a near-term bounce following the completion of filing of EUA filing with the FDA, but it may not be a…
Why I’m Done With Novavax Stock
Management is terrible at delivering on its promises and even good news has failed to translate into higher prices for NVAX stock.
Ocugen Stock: The Two What-If Scenarios To Consider
OCGN stock is now facing an all or nothing business development and is at a very critical stage so it is wise to avoid it.
Covid Vaccine Update: How Do the Moderna and Pfizer Coronavirus Vaccines Compare?
With a new Covid vaccine update today, how do the Moderna and Pfizer coronavirus vaccines compare? Dive in here.
NVAX Stock Alert: The Covid-19 Vaccine News Sending Novavax Higher Today
News that Australia has received its first shipment of Novavax’s Covid-19 vaccine has NVAX stock taking off nearly 9% in today’s trading.
Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?
Akero Therapeutics (stock is falling hard on Tuesday after the company failed to impress AKRO investors with its clinical trial results.
Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?
BioXcel Therapeutics (BTAI) stock is taking a beating on Thursday after the company released its latest clinical trial data.
Developed World Boosters Offer Big Market for Eventual Novavax Vaccine
Novavax’s combination vaccine and its Covid-19 vaccine sales for Q1/2022 in Japan are positive drivers for its revenue in the years ahead.
5 – 10 of 240 results
